Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)
ID: 352183Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352183

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-123.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for a cooperative agreement to establish a Clinical Coordinating Center (CCC) as part of multi-site, investigator-initiated clinical trials focused on evaluating the efficacy of natural products, including botanicals and dietary supplements. Applicants are required to present comprehensive scientific and operational plans, demonstrating substantial preliminary data on the safety and bioavailability of the proposed natural products, and must also include a Plan for Enhancing Diverse Perspectives (PEDP) as part of their submission. This funding opportunity, designated as PAR-24-123, emphasizes the NIH's commitment to exploring complementary health strategies through rigorous scientific investigation, with applications due by July 15, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-123-Full-Announcement.html
    PAR-24-123.html
    The National Institutes of Health (NIH) is inviting cooperative agreement applications for the establishment of a Clinical Coordinating Center (CCC) as part of multi-site, investigator-initiated clinical trials aimed at evaluating natural products, including botanicals and dietary supplements. This funding opportunity, designated as PAR-24-123, emphasizes rigorous investigation into the efficacy of natural products, requiring applicants to present comprehensive scientific and operational plans. A two-phase cooperative agreement funding mechanism, UG3/UH3, will be employed to facilitate trial setup and implementation. The CCC's responsibilities include managing project logistics, participant recruitment, and maintaining scientific integrity, while an accompanying Data Coordinating Center (DCC) is mandated to ensure independent data management and analysis. The NOFO emphasizes the necessity for a Plan for Enhancing Diverse Perspectives (PEDP), which will be a key component of the application evaluation. Additionally, applicants must demonstrate substantial preliminary data validating the proposed natural products, including evidence of safety and bioavailability. The NIH encourages early interaction with its scientific staff to refine proposals and align them with their strategic research priorities. This funding initiative highlights the NIH's dedication to exploring complementary health strategies through scientifically rigorous approaches.
    Similar Opportunities
    NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), is inviting applications for the "NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)" grant, aimed at advancing research on natural products such as botanicals and dietary supplements. This funding opportunity encourages mid-phase clinical trials that are hypothesis-driven, focusing on determining optimal dosing or identifying patient phenotypes for future efficacy studies, while explicitly excluding trials for cancer treatment. Eligible applicants include a diverse range of organizations, such as historically black colleges, tribal colleges, and community-based organizations, with a funding ceiling of $350,000 and a submission deadline of November 13, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-24-115.html.
    NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), invites applications for the NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33), aimed at supporting early-phase clinical trials of natural products such as botanicals and dietary supplements. This funding opportunity encourages research that evaluates the pharmacokinetics, safety, and efficacy of these natural products, with a focus on advancing promising interventions backed by prior scientific evidence. The program is designed to foster innovative clinical research that enhances understanding of the beneficial impacts of natural products on health conditions, while ensuring inclusivity through a Plan for Enhancing Diverse Perspectives (PEDP). Applicants may request up to $350,000 per year, with a project duration of up to six years contingent upon successful milestone completion, and the application deadline is November 13, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCCIH Natural Product Early Phase Clinical Trial Award (R33), aimed at funding early phase clinical trials focused on natural products such as botanicals and dietary supplements. This funding opportunity encourages research that rigorously evaluates the effects of these products on specific biological targets, with a total budget limit of $1,050,000 in direct costs available for up to three years of support. The initiative is particularly relevant for addressing health issues like chronic pain and gastrointestinal disorders, emphasizing the importance of diverse research collaborations and methodologies. Interested applicants must comply with NIH grants policies and submit their proposals by November 13, 2026, while also enhancing research diversity through a Plan for Enhancing Diverse Perspectives (PEDP). For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the development of a Clinical Coordinating Center (CCC) to support multi-site investigator-initiated clinical trials under the UG3/UH3 activity codes. This initiative aims to foster innovative trial designs relevant to the National Heart, Lung, and Blood Institute's (NHLBI) research mission, requiring comprehensive project plans that address participant recruitment, milestone achievements, and strategies for enhancing community engagement and diversity. The funding mechanism is bi-phasic and necessitates simultaneous applications for both a CCC and a collaborating Data Coordinating Center (DCC), emphasizing strong project management and a commitment to minimizing health disparities. Interested applicants must submit their proposals by September 11, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. More details can be found in the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-192.html.
    Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Data Coordinating Center (DCC) for multi-site investigator-initiated clinical trials under funding opportunity PAR-22-193. This initiative aims to support trials that evaluate efficacy, comparative effectiveness, and implementation strategies relevant to the mission of the National Heart, Lung, and Blood Institute (NHLBI), emphasizing collaboration with a Clinical Coordinating Center (CCC). The DCC will be responsible for comprehensive project coordination, data management, and biostatistical support, ensuring adherence to participant safety and diverse population recruitment. Interested applicants must submit both DCC and CCC applications concurrently by September 11, 2025, and can seek early consultation with NIH staff for guidance. For further details, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-193.html.
    Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Discovery and Development of Natural Products for Cancer Interception and Prevention, specifically through a cooperative agreement mechanism. This initiative aims to support the discovery and development of novel, safe, and effective natural products that target cancer prevention, structured in two phases: the UG3 phase for initial screenings and assay development lasting up to three years, followed by the UH3 phase for full-scale evaluations lasting up to two years. The program emphasizes the importance of high-throughput screening strategies and collaboration with existing NCI natural product libraries, with a total funding allocation of $4.5 million for approximately 12 awards. Interested applicants must submit their proposals by June 13, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for multi-site feasibility clinical trials of mind and body interventions through the National Center for Complementary and Integrative Health (NCCIH). This R01 research grant invites applications focused on investigating complementary health approaches that utilize physical or psychological therapies, with an emphasis on demonstrating prior feasibility data to support the multi-site approach. The initiative aims to enhance understanding of integrative health interventions, particularly their efficacy and impact on diverse populations and health disparities. Interested applicants can apply for a maximum project budget of $350,000 annually over a period not exceeding three years, with a submission deadline of January 20, 2024. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Clinical Coordinating Center (Collaborative UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for a phased multi-site clinical trial aimed at preventing cardiovascular disease (CVD) in young adults with a high lifetime risk, utilizing surrogate outcomes. The primary objective is to establish a Clinical Coordinating Center (CCC) to manage a trial that will screen eligible participants and evaluate interventions to reduce the progression of coronary atherosclerosis among individuals aged 50 and younger, or women over 50. This initiative is significant as it seeks to address critical knowledge gaps regarding the impact of early treatment on subclinical CVD, while also enhancing inclusivity in research participation. Interested applicants should note that the total funding commitment may exceed $30 million, with a maximum project duration of seven years, and the application deadline is October 28, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth." This initiative encourages the submission of proposals for fully remotely conducted clinical trials aimed at assessing the efficacy of complementary and integrative health interventions, particularly in areas designated as high research priorities by the National Center for Complementary and Integrative Health (NCCIH). The trials must involve no in-person contact between research staff and participants, utilizing mobile health technologies, and applicants are required to provide preliminary data demonstrating the feasibility and safety of their proposed approaches, along with a Plan for Enhancing Diverse Perspectives (PEDP) that will be evaluated during the review process. The application period opens on January 20, 2024, with a submission deadline of February 20, 2026. Interested applicants can find more information and guidance at the NIH website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.